Edgestream Partners L.P. acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 152,252 shares of the company’s stock, valued at approximately $5,184,000. Edgestream Partners L.P. owned approximately 0.33% of Omnicell at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. Maryland State Retirement & Pension System raised its stake in Omnicell by 53.0% during the third quarter. Maryland State Retirement & Pension System now owns 10,180 shares of the company’s stock worth $347,000 after acquiring an additional 3,526 shares during the period. Fulcrum Asset Management LLP boosted its holdings in shares of Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock valued at $40,000 after acquiring an additional 1,116 shares in the last quarter. Bridge City Capital LLC boosted its stake in Omnicell by 21.4% during the 3rd quarter. Bridge City Capital LLC now owns 67,444 shares of the company’s stock valued at $2,296,000 after purchasing an additional 11,883 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Omnicell during the third quarter worth about $402,000. Finally, Choreo LLC raised its holdings in shares of Omnicell by 42.9% in the 3rd quarter. Choreo LLC now owns 13,518 shares of the company’s stock worth $460,000 after purchasing an additional 4,060 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.
Omnicell Price Performance
Shares of OMCL opened at $34.66 on Thursday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 21.52, a P/E/G ratio of 0.85 and a beta of 0.88. Omnicell, Inc. has a fifty-two week low of $31.75 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.65 and a quick ratio of 1.45. The business’s 50-day moving average is $35.11 and its 200-day moving average is $38.20.
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.42 by $0.16. The business had revenue of $307.85 million during the quarter, compared to analysts’ expectations of $304.44 million. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same period last year, the company posted $0.51 earnings per share. Equities research analysts expect that Omnicell, Inc. will post 1.64 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on OMCL shares. Wall Street Zen lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Weiss Ratings downgraded shares of Omnicell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, November 9th. BTIG Research reiterated a “neutral” rating on shares of Omnicell in a research report on Friday, November 13th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. Finally, KeyCorp restated an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and a consensus target price of $57.86.
Check Out Our Latest Analysis on OMCL
About Omnicell
Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.
Read More
- Five stocks we like better than Omnicell
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
